PURPOSE: Data on the anti-Xa efficacy of fondaparinux in dialysis-dependent chronic kidney disease (DD-CKD) patients are scarce. This study characterizes the pharmacokinetics (PK) and pharmacodynamics (PD) of fondaparinux in DD-CKD patients undergoing renal replacement therapy (RRT), to assess dosing strategies. METHODS: A retrospective, observational study was conducted using data on anti-Xa activity (112 samples) from 12 (3 male and 9 female) DD-CKD patients (median (IQR) age 71 years (63-88), weight 73 kg (59-98.5)). Eleven patients underwent high-flux or low-flux hemodialysis (HD) and one patient underwent peritoneal dialysis. Three patients were also treated with therapeutic plasma exchange (TPE). A non-linear mixed effects analysis was performed using NONMEM 7.3.0. RESULTS: The lab-specific slope of the relationship between fondaparinux concentration and anti-Xa levels was 1.18 IU/µg. In a one-compartment model, clearance (CL) and volume of distribution (Vd) were 0.05289 L/h and 5.55 L, respectively. High-flux HD was found to increase the CL of fondaparinux 2.26 times. TPE also considerably increased CL, but the fold-change could not be accurately estimated. Low-flux HD and peritoneal dialysis did not impact PK parameters. CONCLUSIONS: Model-based simulations showed that standard dosing (2.5 mg three times weekly before HD) results in a median anti-Xa activity of 0.55 IU/mL and 0.98 IU/mL, pre- and post-low-flux HD, respectively. In patients undergoing high-flux HD, these values are approximately 27% lower. Additional caution is warranted with TPE, as this treatment can reduce anti-Xa activity even further.

Department of Biophysics and Physical Chemistry Faculty of Pharmacy Charles University Hradec Králové Czech Republic

Department of Nephrology 1st Faculty of Medicine Charles University and General University Hospital Prague Czech Republic

Division of Systems Biomedicine and Pharmacology Leiden Academic Centre for Drug Research Leiden University Leiden The Netherlands

Institute of Pharmacology 1st Faculty of Medicine and General University Hospital Charles University Prague Czech Republic

Internal Department of Strahov General University Hospital Prague Czech Republic

Eur J Clin Pharmacol. 2022 Jan;78(1):99. doi: 10.1007/s00228-021-03220-y. PubMed

Zobrazit více v PubMed

Daugirdas J, Blake P, Ing T (2015) Handbook of dialysis. Wolters Kluwer

Haase M, Bellomo R, Rocktaeschel J, Ziemer S, Kiesewetter H, Morgera S, Neumayer HH (2005) Use of fondaparinux (ARIXTRA) in a dialysis patient with symptomatic heparin-induced thrombocytopaenia type II. Nephrol Dial Transplant 20(2):444–446. https://doi.org/10.1093/ndt/gfh544 PubMed DOI

Brown P, Jay R, Fox A, Oliver M (2013) Chronic fondaparinux use in a hemodialysis patient with heparin-induced thrombocytopenia type II and extracorporeal circuit thrombosis-a case report and review of the literature. Hemodial Int 17(3):444–449. https://doi.org/10.1111/hdi.12003 PubMed DOI

Taskapan H, Karahan D, Kuku I, Koc S (2010) Heparin-induced thrombocytopenia as a cause of deep venous thrombosis: effectiveness of fondaparinux in dialysis patients. Turkish Nephrology Dialysis Transplantation 19:55–57. https://doi.org/10.5262/tndt.2010.1001.09 DOI

European Medicines Agency (2021) ( https://www.ema.europa.eu/en/medicines/human/EPAR/arixtra#product-information-section , accessed 06/23/2021) Arixtra: Summary of Product Characteristics

Speeckaert MM, Devreese KM, Vanholder RC, Dhondt A (2013) Fondaparinux as an alternative to vitamin K antagonists in haemodialysis patients. Nephrol Dial Transplant 28(12):3090–3095. https://doi.org/10.1093/ndt/gft293 PubMed DOI

Mahieu E, Claes K, Jacquemin M, Evenepoel P, Op De Beek K, Bogaert AM, Kuypers D, Verhamme P, Meijers B (2013) Anticoagulation with fondaparinux for hemodiafiltration in patients with heparin-induced thrombocytopenia: dose-finding study and safety evaluation. Artif Organs 37(5):482–487. https://doi.org/10.1111/aor.12002 PubMed DOI

Hartinger JM, Svobodová A, Malíková I, Šachl R, Slanař O (2020) Effective use of fondaparinux in patient with unresponsiveness to nadroparin. J Clin Pharm Ther. https://doi.org/10.1111/jcpt.13328 PubMed DOI

Kalicki RM, Aregger F, Alberio L, Lämmle B, Frey FJ, Uehlinger DE (2007) Use of the pentasaccharide fondaparinux as an anticoagulant during haemodialysis. Thromb Haemost 98(6):1200–1207. https://doi.org/10.1160/th07-07-0444 PubMed DOI

Lindbom L, Pihlgren P, Jonsson EN (2005) PsN-Toolkit–a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Prog Biomed 79(3):241–257. https://doi.org/10.1016/j.cmpb.2005.04.005 PubMed DOI

Lindbom L, Ribbing J, Jonsson EN (2004) Perl-speaks-NONMEM (PsN)–a Perl module for NONMEM related programming. Comput Methods Prog Biomed 75(2):85–94. https://doi.org/10.1016/j.cmpb.2003.11.003 PubMed DOI

Keizer RJ, van Benten M, Beijnen JH, Schellens JH, Huitema AD (2011) Pirana and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Prog Biomed 101(1):72–79. https://doi.org/10.1016/j.cmpb.2010.04.018 PubMed DOI

Donat F, Duret JP, Santoni A, Cariou R, Necciari J, Magnani H, de Greef R (2002) The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet 41(Suppl 2):1–9. https://doi.org/10.2165/00003088-200241002-00001 PubMed DOI

Comets E, Brendel K, Mentré F (2008) Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Prog Biomed 90(2):154–166 DOI

De Cock RF, Piana C, Krekels EH, Danhof M, Allegaert K, Knibbe CA (2011) The role of population PK–PD modelling in paediatric clinical research. Eur J Clin Pharmacol 67(1):5–16 DOI

Paolucci F, Claviés MC, Donat F, Necciari J (2002) Fondaparinux sodium mechanism of action: identification of specific binding to purified and human plasma-derived proteins. Clin Pharmacokinet 41(Suppl 2):11–18. https://doi.org/10.2165/00003088-200241002-00002 PubMed DOI

Cope J, Bushwitz J, An G, Antigua A, Patel A, Zumberg M (2015) Clinical experience with prophylactic fondaparinux in critically ill patients with moderate to severe renal impairment or renal failure requiring renal replacement therapy. Ann Pharmacother 49(3):270–277. https://doi.org/10.1177/1060028014563325 PubMed DOI

Delavenne X, Zufferey P, Nguyen P, Rosencher N, Samama CM, Bazzoli C, Mismetti P, Laporte S (2012) Pharmacokinetics of fondaparinux 1.5 mg once daily in a real-world cohort of patients with renal impairment undergoing major orthopaedic surgery. Eur J Clin Pharmacol 68 (10):1403–1410. https://doi.org/10.1007/s00228-012-1263-0

Cheng CW, Hendrickson JE, Tormey CA, Sidhu D (2017) Therapeutic plasma exchange and its impact on drug levels: an ACLPS critical review. Am J Clin Pathol 148(3):190–198. https://doi.org/10.1093/ajcp/aqx056 PubMed DOI

Turpie A (2004) Fondaparinux: a factor Xa inhibitor for antithrombotic therapy. Expert Opin Pharmacother 5:1373–1384. https://doi.org/10.1517/14656566.5.6.1373 PubMed DOI

Ho G, Leblanc K, Selby R, Richardson R, Hladunewich M, Battistella M (2013) Use of fondaparinux for circuit patency in hemodialysis patients. Am J Kidney Dis 61(3):525–526. https://doi.org/10.1053/j.ajkd.2012.09.015 PubMed DOI

Sombolos KI, Fragia TK, Gionanlis LC, Veneti PE, Bamichas GI, Fragidis SK, Georgoulis IE, Natse TA (2008) Use of fondaparinux as an anticoagulant during hemodialysis: a preliminary study. Int J Clin Pharmacol Ther 46(4):198–203 DOI